Skip to main content

Christina Poh, MD

Christina Poh, MD

Physician, Fred Hutchinson Cancer Center
Assistant Professor, Division of Hematology and Oncology
University of Washington School of Medicine
Seattle, Washington

In light of the unmet need for improving response rates in relapsed/resistant cases of persons with PTCL-TFH, how did your group identify the dual delta-gamma PI3K inhibitor, duvelisib, for managing R/R cases?

In light of the unmet need for improving response rates in relapsed/resistant cases of persons with PTCL-TFH, how did your group identify the dual delta-gamma PI3K inhibitor, duvelisib, for managing R/R cases?

Christina Poh, MD

Can you discuss what the current post-CHOP therapy landscape looks like for persons with PTCL-TFH, in particular for patients who have relapsed, failed, and/or are resistant to CHOP?

Can you discuss what the current post-CHOP therapy landscape looks like for persons with PTCL-TFH, in particular for patients who have relapsed, failed, and/or are resistant to CHOP?

Christina Poh, MD

Can you discuss your experience with duvelisib in persons with the PTCL-TFH subtype and what range of response rates you have observed, as well as your deployment of duvelisib as bridge therapy for patients awaiting allograft stem cell transplant?

Can you discuss your experience with duvelisib in persons with the PTCL-TFH subtype and what range of response rates you have observed, as well as your deployment of duvelisib as bridge therapy for patients awaiting allograft stem cell transplant?

Christina Poh, MD

Trials such as PRIMO have reported on multiple dosing regimens of duvelisib. How do you dose duvelisib in the R/R setting and when used for bridging in patients awaiting allograft stem cell transplantation?

Trials such as PRIMO have reported on multiple dosing regimens of duvelisib. How do you dose duvelisib in the R/R setting and when used for bridging in patients awaiting allograft stem cell transplantation?

Christina Poh, MD

How do you use the NCCN guidelines, and specifically, their specific recommendations endorsing duvelisib as both monotherapy and in combination with romidepsin?

How do you use the NCCN guidelines, and specifically, their specific recommendations endorsing duvelisib as both monotherapy and in combination with romidepsin?

Christina Poh, MD

What current ongoing studies are evaluating the role of duvelisib as part of a first-line combinatorial regimen that would be used along with CHOP upon confirmation of PTCL-TFH?

What current ongoing studies are evaluating the role of duvelisib as part of a first-line combinatorial regimen that would be used along with CHOP upon confirmation of PTCL-TFH?

Christina Poh, MD

What is the adverse event profile for duvelisib in your clinical experience and how do you manage and mitigate these side effects in the real world management of patients with R/R PTCL-TFH?

Christina Poh, MD

At what point with PTCL-TFH do you introduce duvelisib treatment? Do you use it in the first-line setting or do you currently reserve it for R/R patients and as a bridge for allograft stem cell transplantion?

At what point with PTCL-TFH do you introduce duvelisib treatment? Do you use it in the first-line setting or do you currently reserve it for R/R patients and as a bridge for allograft stem cell transplantion?

Christina Poh, MD

In your view, what are the most important unmet needs in clinical trial design for PTCL-TFH?

In your view, what are the most important unmet needs in clinical trial design for PTCL-TFH?

Christina Poh, MD

What do you see as the near future role of duvelisib in this patient subgroup, even before the results of the TERZO trial are reported?

What do you see as the near future role of duvelisib in this patient subgroup, even before the results of the TERZO trial are reported?

Christina Poh, MD

What’s your rationale for duvelisib dosing in: (1) bridging to allogeneic transplant, (2) achieving CR in R/R PTCL-TFH, and (3) palliative care?

What’s your rationale for duvelisib dosing in: (1) bridging to allogeneic transplant, (2) achieving CR in R/R PTCL-TFH, and (3) palliative care?

Christina Poh, MD

Based on your real world experience with duvelisib in PTCL-TFH, what role do you see for this agent?

Based on your real world experience with duvelisib in PTCL-TFH, what role do you see for this agent?

Christina Poh, MD